Yen Bai, March 22, 2024 - Bayer Vietnam has sponsored 500,000 boxes of multi-vitamin supplement in the form of effervescent tablets to support the Vietnam Young Physicians' Association (VYPA)'s humanitarian medical services. These effervescent multivitamin tablets, supporting everyday energy release, helping reduce tiredness and fatigue, will reach individuals in need across 49 provinces, with a focus on those facing financial hardship or limited healthcare access in remote areas.

The handover ceremony coincided with VYPA kicking off the "Free Medical Examination Campaign and Technology Transfer to Hospitals in Ethnic Minority Areas" program in Cam An commune, Yen Binh district, Yen Bai province. The event was attended by leaders from the Ministry of Health, Yen Bai Province, and a team of volunteering doctors. Nearly 1,000 local residents received free health screenings, consultations, and necessary medication during this event.

Ms. Tran Thi Lan Huong, Medical Director of Bayer Vietnam, commented on this activity: "This year marks our 30th anniversary of operating in Vietnam. We're honored to support the work of the Vietnam Young Physicians' Association during such an important milestone. For three decades, Bayer has been committed to partnering with local organizations that share our vision of improving community health, especially for those facing challenges accessing care. This initiative is a meaningful way for us to celebrate Bayer Vietnam’s anniversary by demonstrating our long-term dedication to delivering patient-centered healthcare solutions. It moves us closer to realizing our global mission - a future where Health for All, Hunger for None."

Dr. Ha Anh Duc, President of the Vietnam Young Physicians’ Association shared: “With the guiding principle of 'Where there are young doctors, there will be humanitarian medical initiatives for the community,' the Vietnam Young Physicians' Association has stayed committed to providing humanitarian medical care program to underserved populations. We are grateful for partners like Bayer who share our vision of elevating health standards and quality of life for people nationwide. This contribution provides us with additional resources to expand and enhance the reach and impact of our activities, facilitating earlier illness detection and treatment, raising health awareness, encouraging healthy lifestyle, and emphasizing the important of self-care practices.”

This initiative with VYPA is an important part of Bayer's larger Patient Support Program, which has been implemented in close cooperation with the Ministry of Health and followed the guidance of the Department of Medical Services Administration. Through this program, the company has offered nearly 2 million boxes of multivitamin supplement to vulnerable groups in Vietnam free of charge. These products are delivered through partner organizations that conduct medical screening and treatment. Distribution began in December 2023, and to date more than 1,700 boxes have been provided to healthcare centers across 12 provinces.

The program aims to make high-quality nutrition more accessible for underserved communities nationwide and ensures those most in need can access vital supplements for their health and well-being, fostering equitable healthcare for all Vietnamese citizens.


About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.


^{Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.}